Dr. Otis Brawley Named to Agilent Board of Directors
November 18 2021 - 04:05PM
Business Wire
Leading authority on cancer research joins
Agilent board
Agilent Technologies, Inc. (NYSE: A) today announced that Dr.
Otis W. Brawley, a Bloomberg Distinguished Professor with the
Department of Oncology and Epidemiology at the Johns Hopkins
University School of Medicine, has been elected to Agilent’s board
of directors, effective Nov. 17, 2021.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20211118005228/en/
Dr. Otis Brawley, a Bloomberg
Distinguished Professor with the Department of Oncology and
Epidemiology at the Johns Hopkins University School of Medicine,
has joined the Agilent Board of Directors. (Photo: Business
Wire)
Dr. Brawley is a leading authority on cancer screening and
prevention, with a focus on closing racial, economic, and social
inequalities in the prevention, detection, and treatment of cancer.
In addition to his role at Johns Hopkins, he is a member of the
National Cancer Institute Board of Scientific Advisors and the
National Academy of Medicine.
“It’s a special honor to have someone with Otis’ deep academic
and medical expertise join the Agilent board,” said Mike McMullen,
Agilent president and CEO. “His involvement and leadership in
oncology research will provide Agilent with important insights and
perspectives. As Agilent expands its focus in cancer diagnostics,
we are ensuring we have the expertise on our board to be a
successful, forward-thinking, thoughtful leader in this space.”
“We’re very pleased to welcome Otis to the Agilent board,” said
Koh Boon Hwee, chair of the Agilent board. “I’m extremely confident
we will benefit from his ongoing active leadership in oncology
research and the issues that need to be addressed in order to
ensure the best possible outcomes for all cancer patients.”
Prior to assuming his current role at Johns Hopkins in 2019, Dr.
Brawley served for 11 years as chief medical and scientific officer
and executive vice president for Research at the American Cancer
Society. In that position, he oversaw the largest private program
funding cancer research in the U.S. In addition, Dr. Brawley has
also served as director, Georgia Cancer Center and chief of
Hematology and Oncology at Grady Memorial Hospital in Atlanta. Dr.
Brawley has also previously served in a medical and academic role
at Emory University and in a variety of roles with the National
Cancer Institute.
Dr. Brawley was a Georgia Cancer Coalition Scholar and received
the Key to St. Bernard Parish and the U.S. Public Health Service
(PHS) Meritorious Service Medal for his work as a PHS Commissioned
Officer in the aftermath of Hurricane Katrina in 2005. He is also a
recipient of the U.S. Dept. of Defense Distinguished Service Medal
for his contributions to military medical education and received
the Distinguished Service Award from the American Medical
Association in 2019.
Dr. Brawley is currently a member of the board of directors at
public biotech companies Incyte Corporation, Lyell Immunopharma and
PDS Biotechnology.
He received both his bachelor’s degree in chemistry and his
medical degree from the University of Chicago.
About Agilent Technologies Agilent Technologies Inc.
(NYSE: A) is a global leader in life sciences, diagnostics, and
applied chemical markets, delivering insight and innovation toward
improving the quality of life. Agilent instruments, software,
services, solutions, and people provide trusted answers to
customers' most challenging questions. The company generated
revenue of $5.34 billion in fiscal year 2020 and employs 16,400
people worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, please
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn,
Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211118005228/en/
Media Contact: Tom Beermann +1 408 386 5892
tom.beermann@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Feb 2024 to Mar 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2023 to Mar 2024